Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for JW Pharmaceutical Co., Ltd. Preferred Stock (001065:KRX), powered by AI.
JW Pharmaceutical Co., Ltd. Preferred Stock is currently trading at ₩21,050. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for JW Pharmaceutical Co., Ltd. Preferred Stock on Alpha Lenz.
JW Pharmaceutical Co., Ltd. Preferred Stock's P/E ratio is 0.1.
“JW Pharmaceutical Co., Ltd. Preferred Stock trades at a P/E of 0.1 (undervalued) with strong ROE of 17.6%.”
Ask for details →JW Pharmaceutical Co., Ltd. Preferred Stock is a type of equity security that represents a claim on the company's assets and earnings. Unlike common stock, preferred stock typically comes with no voting rights, but it may offer greater dividend security in the form of fixed periodic dividend payments. This makes it an attractive option for those seeking a more stable income stream compared to common stock. JW Pharmaceutical operates in the pharmaceutical sector, focusing on developing, manufacturing, and distributing various medicines, which positions it in a critical and continuously evolving industry. Preferred stocks like those issued by JW Pharmaceutical are often seen as a hybrid between bonds and common stocks, providing elements of both equity growth and fixed income. In the financial market, this type of asset serves as a tool for diversifying investment portfolios, balancing the risk, and aiding in income generation, particularly in sectors that are essential and demonstrate resilience in various economic climates.
“JW Pharmaceutical Co., Ltd. Preferred Stock trades at a P/E of 0.1 (undervalued) with strong ROE of 17.6%.”
Ask for details →JW Pharmaceutical Co., Ltd. Preferred Stock (ticker: 001065) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,048 employees. Market cap is $7.2B.
The current price is ₩21,050 with a P/E ratio of 0.12x and P/B of 0.02x.
ROE is 17.60% and operating margin is 12.18%. Annual revenue is $775.3B.